Neuren Pharmaceuticals Limited
NURPFOTCHealthcare● Active
$9.25
+$0.38(+4.23%)
Market Cap$1.2B
P/E Ratio—
52W High$14.7965
52W Low$7.7
Neuren Pharmaceuticals Limited (NURPF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NURPF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $64.61M | $216.83M | $231.93M | $14.55M | $3.20M |
| Cost of Revenue | $0.02M | $32.97M | $26.75M | $0.01M | $0.01M |
| Gross Profit | $64.59M | $183.86M | $205.17M | $14.54M | $3.19M |
| Gross Margin %(computed) | 99.96% | 84.79% | 88.47% | 99.93% | 99.75% |
| Operating Expenses | |||||
| R&D Expenses | $36.38M | $32.97M | $26.75M | $12.71M | $9.52M |
| G&A Expenses | $0.00M | $4.70M | $5.95M | $3.44M | $1.91M |
| Total Operating Expenses | $42.57M | $37.69M | $32.70M | $16.14M | $11.42M |
| Operating Income | $22.02M | $146.19M | $172.49M | ($1.60M) | ($17.75M) |
| Operating Margin %(computed) | 34.07% | 67.42% | 74.37% | -10.97% | -555.18% |
| Interest Income | $12.15M | $11.01M | $5.69M | $0.39M | $0.04M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | $38.91M | $182.94M | $205.14M | ($0.68M) | ($7.79M) |
| Income Tax Expense | $8.49M | $40.90M | $48.06M | ($0.86M) | $0.00M |
| Net Income | $30.42M | $142.04M | $157.08M | $0.18M | ($7.79M) |
| Net Margin %(computed) | 47.09% | 65.51% | 67.73% | 1.26% | -243.79% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.24 | $1.09 | $1.24 | $0.00 | $-0.07 |
| Wtd Avg Shares | 128.24M | 130.78M | 127.07M | 125.97M | 117.77M |
| EBITDA | $22.04M | $179.18M | $199.26M | ($0.72M) | ($8.22M) |
| EBITDA Margin %(computed) | 34.11% | 82.64% | 85.92% | -4.96% | -257.27% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · AUD · M
Explore more Neuren Pharmaceuticals Limited data
About Neuren Pharmaceuticals Limited (NURPF) Income Statement
Neuren Pharmaceuticals Limited (NURPF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NURPF reported revenue of $0.06B, gross profit of $0.06B (gross margin 99.96%), and net income of $0.03B — a net profit margin of 47.09%.
Frequently asked questions
NURPF · 4 questionsNeuren Pharmaceuticals Limited (NURPF) reported revenue of $0.06B for 2025, down 70.2% year-over-year.
NURPF revenueNURPF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09